The stock of Idexx Laboratories, Inc (IDXX) has gone down by -6.45% for the week, with a 1.15% rise in the past month and a -1.17% drop in the past quarter. The volatility ratio for the week is 2.89%, and the volatility levels for the past 30 days are 2.71% for IDXX. The simple moving average for the past 20 days is -6.78% for IDXX’s stock, with a -8.94% simple moving average for the past 200 days.
Is It Worth Investing in Idexx Laboratories, Inc (NASDAQ: IDXX) Right Now?
Idexx Laboratories, Inc (NASDAQ: IDXX) has a higher price-to-earnings ratio of 39.71x compared to its average ratio, The 36-month beta value for IDXX is at 1.38. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 4 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for IDXX is 80.50M, and currently, shorts hold a 2.62% of that float. The average trading volume for IDXX on February 28, 2025 was 658.98K shares.
IDXX) stock’s latest price update
Idexx Laboratories, Inc (NASDAQ: IDXX)’s stock price has gone decline by -3.96 in comparison to its previous close of 441.03, however, the company has experienced a -6.45% decrease in its stock price over the last five trading days. zacks.com reported 2025-02-18 that IDEXX’s robust strength in the CAG Diagnostics business and strong global performance are highly promising.
Analysts’ Opinion of IDXX
Many brokerage firms have already submitted their reports for IDXX stocks, with Leerink Partners repeating the rating for IDXX by listing it as a “Outperform.” The predicted price for IDXX in the upcoming period, according to Leerink Partners is $500 based on the research report published on December 02, 2024 of the previous year 2024.
BTIG Research, on the other hand, stated in their research note that they expect to see IDXX reach a price target of $580. The rating they have provided for IDXX stocks is “Buy” according to the report published on July 25th, 2024.
Piper Sandler gave a rating of “Neutral” to IDXX, setting the target price at $525 in the report published on January 30th of the previous year.
IDXX Trading at -2.49% from the 50-Day Moving Average
After a stumble in the market that brought IDXX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.40% of loss for the given period.
Volatility was left at 2.71%, however, over the last 30 days, the volatility rate increased by 2.89%, as shares surge +1.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.64% lower at present.
During the last 5 trading sessions, IDXX fell by -5.17%, which changed the moving average for the period of 200-days by -15.79% in comparison to the 20-day moving average, which settled at $454.63. In addition, Idexx Laboratories, Inc saw 2.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IDXX starting from FENNELL GEORGE, who sale 9,986 shares at the price of $462.53 back on Feb 10 ’25. After this action, FENNELL GEORGE now owns 8,176 shares of Idexx Laboratories, Inc, valued at $4,618,862 using the latest closing price.
FENNELL GEORGE, the Officer of Idexx Laboratories, Inc, proposed sale 9,966 shares at $463.46 during a trade that took place back on Feb 10 ’25, which means that FENNELL GEORGE is holding shares at $4,618,863 based on the most recent closing price.
Stock Fundamentals for IDXX
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.61 for the gross margin
The net margin for Idexx Laboratories, Inc stands at 0.23. The total capital return value is set at 0.51. Equity return is now at value 57.66, with 27.10 for asset returns.
Based on Idexx Laboratories, Inc (IDXX), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 5.54. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is 36.21.
Currently, EBITDA for the company is 1.27 billion with net debt to EBITDA at -0.09. When we switch over and look at the enterprise to sales, we see a ratio of 8.85. The receivables turnover for the company is 8.23for trailing twelve months and the total asset turnover is 1.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
In conclusion, Idexx Laboratories, Inc (IDXX) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
